
This trial assessed the dose-response, efficacy and safety of delgocitinib cream in CHE. In this double-blind, phase IIb dose-ranging trial, adults with CHE and a recent history of inadequate response or contraindication to topical corticosteroids were randomized to delgocitinib cream 1, 3, 8, 20 mg g–1 or vehicle treatment twice daily for 16 weeks. The primary endpoint was the Investigator’s Global Assessment for CHE (IGA-CHE) treatment success. Patients (n = 258) were randomized 1 : 1 : 1 : 1 : 1 to delgocitinib cream 1, 3, 8, 20 mg g–1 or vehicle. A significant dose-response relationship was established for IGA-CHE (P < 0.025). Delgocitinib 8 and 20 mg g–1 showed a treatment effect against the vehicle (P < 0.001). Similarly, there were improvements in HECSI, itch and pain NRS scores, and PaGA. In this trial, delgocitinib cream showed a dose-response relationship in efficacy and was well tolerated.
Like
Save
Share